VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress across its diagnostics portfolio. The company announced the submission of a feline lymphoma manuscript, which is tied to a potential $5 million milestone payment. This development underscores Volition's commitment to advancing its novel epigenetic blood tests for both human and animal health.
In addition to the manuscript submission, Volition reported continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies. These discussions are part of the company's strategy to commercialize its proprietary Nu.Q technology platform, which detects circulating nucleosomes and enables early disease detection.
Volition also highlighted advancements across its diagnostic pipeline. The company is making validation progress for its Capture-Seq cancer detection platform, which combines nucleosome capture with next-generation sequencing to identify multiple cancer types from a single blood sample. Furthermore, the sepsis-focused Nu.Q NETs program is expanding, with ongoing studies aimed at improving early detection and monitoring of sepsis, a life-threatening condition.
In Europe, Volition is pursuing reimbursement for its lung cancer assay in France ahead of anticipated routine clinical use. Securing reimbursement is a critical step toward making the test widely available to patients and physicians, potentially improving outcomes for lung cancer patients through earlier detection.
The implications of these developments are significant. If successful, Volition's blood tests could transform cancer diagnostics by providing simple, cost-effective alternatives to invasive biopsies. Early detection is known to improve survival rates and quality of life for patients. Additionally, the Nu.Q NETs program could address a major unmet need in sepsis management, where timely intervention is crucial.
Volition is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, the company develops and commercializes blood tests to help detect and monitor diseases such as cancer and sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S., and an office in London.
For further information, visit the company's website at https://volition.com/.
